Abstract
The
contextual signals that regulate the expansion of prostate tumor progenitor
cells are poorly defined. We found that a significant fraction of advanced
human prostate cancers and castration-resistant metastases express high levels
of the β4 integrin, which binds to laminin-5. Targeted deletion of the
signaling domain of β4 inhibited prostate tumor growth and progression in
response to loss of p53 and Rb function in a mouse model of prostate cancer
(PB-TAg mice). Additionally, it suppressed Pten loss-driven prostate
tumorigenesis in tissue recombination experiments. We traced this defect back
to an inability of signaling-defective β4 to sustain self-renewal of putative cancer
stem cells in vitro and proliferation of transit-amplifying cells in vivo.
Mechanistic studies indicated that mutant β4 fails to promote transactivation
of ErbB2 and c-Met in prostate tumor progenitor cells and human cancer cell
lines. Pharmacological inhibition of ErbB2 and c-Met reduced the ability of
prostate tumor progenitor cells to undergo self-renewal in vitro. Finally, we
found that β4 is often coexpressed with c-Met and ErbB2 in human prostate
cancers and that combined pharmacological inhibition of these receptor tyrosine
kinases exerts antitumor activity in a mouse xenograft model. These findings
indicate that the β4 integrin promotes prostate tumorigenesis by amplifying
ErbB2 and c-Met signaling in tumor progenitor cells.
Source: β4
Integrin signaling induces expansion of prostate tumor progenitors. Yoshioka T,
Otero J, Chen Y, Kim YM, Koutcher JA, Satagopan J, Reuter V, Carver B, de
Stanchina E, Enomoto K, Greenberg NM, Scardino PT, Scher HI, Sawyers CL,
Giancotti FG (f-giancotti@ski.mskcc.org).
J Clin Invest. 2013 Jan 25.
Free
paper available at:
Aucun commentaire:
Enregistrer un commentaire